


Data Sheet

| | |
|--------------------|---|
| Product Name: | SBI-115 |
| Cat. No.: | CS-0043229 |
| CAS No.: | 882366-16-7 |
| Molecular Formula: | C ₁₄ H ₁₃ ClN ₂ O ₄ S |
| Molecular Weight: | 340.78 |
| Target: | GPCR19 |
| Pathway: | GPCR/G Protein |
| Solubility: | DMSO : 150 mg/mL (440.17 mM; Need ultrasonic); H ₂ O : < 0.1 mg/mL (insoluble) |



BIOLOGICAL ACTIVITY:

SBI-115 is a **TGR5 (GPCR19)** antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5^[1]. **In Vitro:** SBI-115 (100-200 μM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Tauro lithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes^[1].

References:

[1]. Masyuk TV, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling. Hepatology. 2017 Oct; 66(4):1197-1218.

CAIndexNames:

4-Pyrimidinecarboxylic acid, 5-chloro-2-(ethylsulfonyl)-, 3-methylphenyl ester

SMILES:

O=C(C1=NC(S(=O)(CC)=O)=NC=C1Cl)OC2=CC=CC(C)=C2

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA